View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 22, 2020updated 06 Dec 2021 11:45am

Abbott’s Covid-19 test shows strong agreement to PCR instruments

Abbott has reported that its ID NOW Covid-19 rapid test showed strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments based on an interim analysis of an ongoing multi-site clinical study in urgent care clinics.

Abbott has reported that its ID NOW Covid-19 rapid test showed strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments based on an interim analysis of an ongoing multi-site clinical study in urgent care clinics.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Launched in 2014, ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. It is a molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the US.

Compared to two different lab-based PCR reference methods, the data from the interim results demonstrated ≥94.7% sensitivity and ≥98.6% specificity of the test.

The study evaluated samples from 256 patients and compared the results to a test developed by the US Centers for Disease Control and Prevention (CDC).

Abbott Rapid Diagnostics infectious disease senior medical director Philip Ginsburg said: “We are pleased that ID NOW is delivering on what it was designed to do – quickly detect the virus in people who need to know now if they are infected.

“This is great news for people who are experiencing symptoms and want to take action before they infect others, reducing the spread of infection in society.”

The test delivers results quickly and helps to reduce the spread of infection by detecting Covid-19-positive patients faster.

The Everett Clinic in Washington, US, and an ongoing study of hospitalised and nursing home patients sponsored by Abbott also suggest that ID NOW performs best in patients tested earlier post-symptom onset.

The studies analysed ID NOW with variations in patient populations based on the number of days a patient was tested after first experiencing symptoms.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network